|

Darzalex Faspro (Daratumumab and hyaluronidase-fihj) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Early 1: 1

Top Sponsors

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1

Indications

  • Bone Marrow Transplant Rejection1
  • Acute Lymphoblastic Leukemia (ALL), Adult1
  • Myelodysplastic Syndromes (MDS)1
  • Myelofibrosis1
  • Chronic Myeloid Leukemia1

Baltimore, Maryland1 trial

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.